Sandoz bets big on biosimilars, aims to double group sales by 2035

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will invest an additional $300 million in a Slovenian biosimilar manufacturing facility.